Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic Rhinosinusitis

Bionorica

Status and phase: Completed; Phase 3

Conditions: Chronic Sinusitis

Treatments: Drug: BNO 1016

Study type: Interventional

Funder types: Industry

Identifiers

NCT01706484

2011-003623-35 (EudraCT Number)

CRS-02

Details and patient eligibility

About

The purpose of this trial is to determine whether 2 different dosages of a herbal extract (240 and 480 mg/day) are more effective than placebo in the treatment of patients with chronic rhinosinusitis (average reduction of investigator's Major Symptom Score over Visit 5 and Visit 6.

Full description

The clinical trial population consists of patients presenting with two or more typical symptoms of CRS and duration of symptoms of at least ≥12 weeks. The diagnosis should have been confirmed with the initial diagnosis of CRS by nasal endoscopy and/or computer tomography (CT) and by obligatory nasal endoscopy including exclusion of nasal polyps during screening phase.

A total of 885 patients will be included in this clinical trial, which will last for approximately 12 months, including screening, treatment and medication-free follow-up period as well as final reporting. The duration for the individual patient is approximately 22 weeks (Visit 1 - Visit 7). After a 2-week screening phase, treatment will be started by application of either 240 mg or 480 mg daily dose (t.i.d.) or placebo for 12 weeks followed by a medication-free follow-up period.

Symptoms often do not correlate to the findings in nasal endoscopy or CT. Therefore, efficacy in this clinical trial is defined as per clinical definition using five individual rhinosinusitis symptoms (MSS)graded by the investigator using increasing severity grading(0 = absent [none / not present], 1 = mild, 2 = moderate, 3 = severe).

Secondary outcome measures include

• single rhinosinusitis symptoms of CRS (MSSINV and MSSPAT),
• Work Productivity and Activity Impairment patient questionnaire related to General Health [WPAI:GH],
• total symptom severity by Visual Analogue Scale
• response to treatment rated by investigator and patient
• 20-Question Sino-Nasal Outcome Test [SNOT-20, only Germany]
• percentage of patients with permitted concomitant medication for the treatment of CRS
• premature termination due to exacerbations of symptoms
• post treatment course of CRS will
• pharmacoeconomic assessments
• safety and tolerability of trial treatment

Enrollment: 927 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent including data protection declaration

• Male and female outpatients aged ≥18 and ≤75 years

• Diagnosis of bilateral chronic rhinosinusitis without nasal polyps confirmed by:

  • nasal endoscopy during the screening period (nasal endoscopy results not older than 2 month will be accepted) to confirm inflammation, mucopurulent discharge and/or oedema/mucosal obstruction primarily in middle meatus without nasal polyps being present
  • at the discretion of the investigator a historic CT (before screening and not older than 24 months) will be considered additionally for confirmation of bilateral involvement of middle meatus and paranasal sinuses without resolution of symptoms (mucosal changes within the ostiomeatal complex and/or sinuses)

• Bilateral chronic rhinosinusitis characterized by (V1 and V2):

  • presence of chronic rhinosinusitis symptoms for at least 12 weeks without complete resolution of symptoms prior to enrolment (V1)
  • a MSS ≥6 points and ≤12 points for each of the screening days observed by diary entries (MSSPAT)and on the days of Visit 1 and 2 (MSSINV)
  • on 5 random days of the screening period (or at least at days -5 to -1) assessed by MSSPAT and on the day of Visit 1 and 2 assessed by MSSINV: rhinorrhoea (anterior or posterior) and pain (facial pain or headache) of at least moderate intensity (score ≥2).

Exclusion criteria

• Sinus surgery within the last 2 years (solitary sinus puncture is allowed)
• Nasal concha surgery within the last 3 months
• Presence or history of uni- or bilateral nasal polyps
• Presence of moderate to severe co-morbid asthma, including allergic asthma
• Patients with mild asthma having exacerbations within 30 days prior to trial inclusion
• Patients with cystic fibrosis
• Patients with a positive skin prick test at V1 against allergens to which the patient might be exposed to during the expected individual trial duration, if clinically relevant (results not older than 12 months will be accepted)
• Clinically relevant perennial (e.g. patients with actual clinical symptoms of allergic rhinitis against house dust/-mite antigen) or actual seasonal allergic rhinitis
• Rhinitis medicamentosa (drug induced rhinitis)
• Aspirin-Exacerbated Respiratory Disease [AERD] (Aspirin sensitivity)
• Dentogenic sinusitis or otherwise unilateral sinusitis
• Presence of anatomical deviations of the nasal septum that significantly impair nasal and paranasal ventilation / airflow
• Known hypersensitivity to trial medication or excipients
• Patients with rare hereditary problems of fructose intolerance, galactose intolerance, lactase deficiency or glucose-galactose malabsorption or sucrase-isomaltase insufficiency
• Signs or symptoms of acute bacterial sinusitis (e.g. fever > 38.5°C, orbital complications,severe unilateral frontal headache or toothache)
• Treatment with systemic or nasal antibiotics or corticosteroids within the last 4 weeks prior to V1
• Treatment with decongestant preparations (α-sympathomimetics), analgesics (including systemic Non-Steroidal Inflammatory Drugs [NSAIDs], except paracetamol), mucolytics / secretolytics, antihistamines, or alternative medicine preparations for treatment of common cold like symptoms or with immunomodulating properties within the last 7 days prior to V1
• Patients with gastric or duodenal ulcer
• Other diseases within 5 years prior to V1, which in the opinion of the investigator disqualifies the patient for trial enrolment (e.g. liver or kidney disease, severe somatopathic, neurological and /or psychiatric diseases, history of malignancy or alcohol or drug abuse or immunodeficiency).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Quadruple Blind

---

927 participants in 3 patient groups, including a placebo group

80 mg BNO 1016 und placebo

Experimental group

Description:

2 tablets (one containing 80 mg BNO 1016 and one placebo) by mouth 3 times daily

Treatment:

Drug: BNO 1016

160 mg BNO 1016

Experimental group

Description:

2 tablets (each containing 80 mg BNO 1016) by mouth 3 times daily

Treatment:

Drug: BNO 1016

placebo

Placebo Comparator group

Description:

2 tablets (each without BNO 1016) by mouth 3 times daily

Treatment:

Drug: BNO 1016